Detalhe da pesquisa
1.
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Cancer
; 128(8): 1595-1604, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35157306
2.
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Blood
; 138(9): 811-814, 2021 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34189565
3.
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
Blood Adv
; 7(7): 1146-1155, 2023 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375132